PRESS RELEASE published on 07/03/2024 at 08:12, 1 year 11 months ago CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities CureVac initiates strategic restructuring to focus on high-value mRNA pipeline opportunities, including workforce reduction and new GSK agreement Oncology Strategic Restructuring CureVac MRNA Pipeline GSK Agreement
PRESS RELEASE published on 07/03/2024 at 08:09, 1 year 11 months ago GSK and CureVac to Restructure Collaboration into New Licensing Agreement GSK and CureVac restructure collaboration into new licensing agreement for mRNA vaccines development, manufacturing, and commercialization globally Licensing Agreement Collaboration GSK MRNA Vaccines CureVac
BRIEF published on 06/24/2024 at 22:10, 1 year 11 months ago CureVac Announces Voting Results of General Meeting Annual General Meeting Voting Results Board Appointments CureVac MRNA
PRESS RELEASE published on 06/24/2024 at 22:05, 1 year 11 months ago CureVac Announces Voting Results of General Meeting CureVac announces voting results of the general meeting, including board appointments and auditor reappointment. Shareholders voted in favor of all proposals Appointments Voting Results General Meeting CureVac Auditor Reappointment
BRIEF published on 05/28/2024 at 13:05, 2 years ago CureVac Announces Dosing of First Participant in Phase 2 Influenza Study GSK MRNA Technology Phase 2 Study CureVac Influenza Vaccine
PRESS RELEASE published on 05/28/2024 at 13:00, 2 years ago CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK CureVac initiates Phase 2 study in collaboration with GSK for seasonal influenza vaccine, targeting improved immune responses against influenza B strain GSK Vaccine Development Phase 2 Study CureVac Seasonal Influenza
BRIEF published on 05/23/2024 at 13:05, 2 years ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update Financial Results Business Update Q1 2024 CureVac FDA Fast Track
PRESS RELEASE published on 05/23/2024 at 13:00, 2 years ago CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update CureVac announces financial results for Q1 2024, reports €300.2 million cash position and updates on organizational restructuring and patent litigations Financial Results Cash Position CureVac Patent Litigation Organizational Redesign
BRIEF published on 04/24/2024 at 13:11, 2 years 1 month ago CureVac Announces 2023 Financial Results and Strategic Business Updates MRNA Technology CureVac Pharmaceutical Collaborations Oncology Vaccines Prophylactic Vaccines
BRIEF published on 04/24/2024 at 13:08, 2 years 1 month ago CureVac Begins Combined Phase 1/2 Study for Avian Influenza H5N1 Vaccine with GSK GSK CureVac Phase 1/2 Study Influenza H5N1 MRNA Vaccine
Published on 06/17/2026 at 16:55, 5 hours 33 minutes ago Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors
Published on 06/17/2026 at 16:45, 5 hours 43 minutes ago Nymox's Nymozarfex(TM) Newly Available for Prostate Treatments for Medical Tourists in Collaboration with the Global Alliance of Regenerative Medicine on Roatan Island in the Caribbean
Published on 06/17/2026 at 14:30, 7 hours 58 minutes ago Solitario Advances 2026 Ponderosa Drilling Program
Published on 06/17/2026 at 14:00, 8 hours 28 minutes ago CHAR Tech Reminds Shareholders of June 18 Investor Update Call
Published on 06/17/2026 at 21:40, 48 minutes ago Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon
Published on 06/17/2026 at 19:10, 3 hours 18 minutes ago Africa Finance Corporation and Leading Italian Institutions Sign Strategic Cooperation Agreements at AFC-Italy Forum to Mobilise Capital and Accelerate Industrial Development Across Africa
Published on 06/17/2026 at 18:40, 3 hours 48 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/17/2026 at 18:36, 3 hours 52 minutes ago BILENDI: Bilendi announces that Euroland Corporate has initiated coverage of its shares
Published on 06/17/2026 at 18:23, 4 hours 5 minutes ago EQS-Adhoc: Ludwig Beck am Rathauseck-Textilhaus Feldmeier AG: Conclusion of a delisting agreement with Bayerische Gewerbebau AG
Published on 06/17/2026 at 17:40, 4 hours 48 minutes ago Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 13 hours 43 minutes ago Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 10 hours ago Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 23 hours ago BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 2 days 3 hours ago Reporting on share buyback transactions carried out between June 8 and June 11, 2026
